Bortezomib Intravenous and Zykadia

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer information for this interaction is not currently available.MONITOR: Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of bortezomib, which is primarily metabolized by the isoenzyme. In a study of 12 patients, administration of bortezomib with the potent inhibitor ketoconazole resulted in a 35% increase in mean bortezomib systemic exposure (AUC) compared to administration alone. MANAGEMENT: Pharmacologic response to bortezomib should be monitored more closely whenever a potent CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the dosage adjusted as necessary. Patients should be monitored for the development of potential bortezomib toxicities such as peripheral neuropathy, orthostatic hypotension, thrombocytopenia, and neutropenia. References Pekol T, Daniels JS, Labutti J, et al "Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites." Drug Metab Dispos 33 (2005): 771-7 "Product Information. Velcade (bortezomib)." Millennium Pharmaceuticals Inc, Cambridge, MA. Uttamsingh V, Lu C, Miwa GT, Gan LS "Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4 to the hepatic metabolism of teh protosome inhibitor bortezomib." Drug Metab Dispos 33 (2005): 1723-8

MONITOR: Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of bortezomib, which is primarily metabolized by the isoenzyme. In a study of 12 patients, administration of bortezomib with the potent inhibitor ketoconazole resulted in a 35% increase in mean bortezomib systemic exposure (AUC) compared to administration alone.

MANAGEMENT: Pharmacologic response to bortezomib should be monitored more closely whenever a potent CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the dosage adjusted as necessary. Patients should be monitored for the development of potential bortezomib toxicities such as peripheral neuropathy, orthostatic hypotension, thrombocytopenia, and neutropenia.

Bortezomib Intravenous

Generic Name: bortezomib

Brand name: Velcade

Synonyms: Bortezomib (Intravenous)

What is Bortezomib Intravenous?

Zykadia

Generic Name: ceritinib

Brand name: Zykadia

Synonyms: n.a.

What is Zykadia?